PRRT2 and plasma cell myeloma: Raab et al. showed that Enzastaurin, a PKC inhibitor, induces an accumulation of β-catenin in multiple myeloma cells by blocking the phosphorylation of β-catenin at Ser33/37 without affecting phosphorylation at Ser45, which prevents its proteasomal degradation.